Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.70 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.70 |
| ▸ | JAK2 | O60674 | 15/20 | 0.65 |
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.55 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4781572 | 0.85 | JAK2 (0.64) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL3756063 | 0.83 | MAPK8 (1.00) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL4734676 | 0.81 | JAK2 (0.71) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL13724670 | 0.80 | JAK2 (0.69) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL12801112 | 0.79 | JAK2 (1.00) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL12274649 | 0.79 | JAK2 (0.77) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL12274500 | 0.79 | CAMK2D (0.81) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL13725012 | 0.79 | JAK2 (0.67) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL30052705 | 0.79 | JAK2 (1.00) | MAPK8MAPK10JAK2JAK3JAK1 | |
| SCHEMBL2880284 | 0.79 | JAK2 (1.00) | MAPK8MAPK10JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | MAPK8 4409/4885MAPK10 3727/4885JAK2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.